KIDNEY HIERARCHICAL COMPOSITE ENDPOINT IN JAPANESE PARTICIPANTS: A POST-HOC SUBGROUP ANALYSIS FROM THE DAPA-CKD TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/260365d106a86a3bf375bd0e68f96f2c.pdf
KIDNEY HIERARCHICAL COMPOSITE ENDPOINT IN JAPANESE PARTICIPANTS: A POST-HOC SUBGROUP ANALYSIS FROM THE DAPA-CKD TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Dustin J
Little
Dustin J Little dustin.little@astrazeneca.com AstraZeneca Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM) Gaithersburg United States *
Samvel B Gasparyan samvel.gasparyan@astrazeneca.com AstraZeneca Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM) Boston United States -
Tomoko Ishizu tomoko.ishizu@astrazeneca.com AstraZeneca K.K. Cardiovascular, Renal, and Metabolism (CVRM) Tokyo Japan -
David Sjostrom david.sjostrom1@astrazeneca.com AstraZeneca Cardiovascular, Renal and Metabolism (CVRM) Gothenburg Sweden -
Naoki Kashihara kashinao@med.kawasaki-m.ac.jp Kawasaki Medical School Department of Nephrology and Hypertension Okayama Japan -
Mototsugu Tanaka mototsugu-tanaka@med.niigata-u.ac.jp Niigata University Medical and Dental Hospital Clinical and Translational Research Center Niigata Japan -
Tetsuhiro Tanaka tetsuhiro.tanaka.d3@tohoku.ac.jp Tohoku University Graduate School of Medicine Division of Nephrology Sendai Japan -
Yuichiro Yano y.yano@juntendo.ac.jp Juntendo University Faculty of Medicine Department of General Medicine, Artificial Intelligence Incubation Farm Tokyo Japan -
Hajime Nagasu HajimeNagasu@kms-ndh.com Kawasaki Medical School Department of Nephrology and Hypertension Okayama Japan -
Kouichi Tamura tamukou@yokohama-cu.ac.jp Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine Yokohama Japan -
Masaomi Nangaku mnangaku@m.u-tokyo.ac.jp The University of Tokyo Graduate School of Medicine Division of Nephrology and Endocrinology Tokyo Japan -
Niels Jongs n.jongs@umcg.nl University of Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands -
Hiddo Heerspink h.j.lambers.heerspink@umcg.nl University of New South Wales The George Institute for Global Health Sydney Australia -
-
-